Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;12(5):1435-1438.
doi: 10.1007/s40120-023-00514-4. Epub 2023 Jun 23.

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Tuan Vu  1 , Andreas Meisel  2 , Renato Mantegazza  3 , Djillali Annane  4 , Masahisa Katsuno  5 , Rasha Aguzzi  6 , Ahmed Enayetallah  6 , Kathleen N Beasley  6 , Nishi Rampal  6 , James F Howard Jr  7
Affiliations

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Tuan Vu et al. Neurol Ther. 2023 Oct.

Abstract

This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB).

Keywords: Anti-AChR antibody; Complement; Monoclonal antibody; Myasthenia gravis; Patient-centered outcomes; Ravulizumab.

PubMed Disclaimer

Conflict of interest statement

Please see original article for full author disclosures.

Figures

Fig. 1
Fig. 1
Study outcome measures over time, and pre-specified responder analyses at 26 weeks. Changes from baseline in MG-ADL total score over time. Changes from baseline in QMG total score over time. Reprinted with permission [1]. Copyright 2022. Massachusetts Medical Society
See this image and copyright information in PMC

References

    1. Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, Enayetallah A, Beasley KN, Rampal N, Howard JF, Jr, for the CHAMPION MG Study Group Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022 doi: 10.1056/EVIDoa2100066. - DOI - PubMed

LinkOut - more resources